25759021_16,s0,T1,T13,Since ,RNF5," is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ",ERS,". To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s0,T1,T2,Since ,RNF5," is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether ",RNF5," interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s0,T2,T13,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether ",RNF5, interaction with Gln-carrier proteins required changes in protein folding following ,ERS,". To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s1,T14,T15,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to ",35S,-methionine-cysteine-based labeling followed by immunopurification of ,35S,"-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s1,T14,T3,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to ",35S,-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled ,SLC1A5," and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s1,T15,T3,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of ",35S,-labeled ,SLC1A5," and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s2,T16,T17,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. ",SDS,-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following ,paclitaxel," treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s2,T16,T4,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. ",SDS,-PAGE analysis followed by autoradiography revealed a marked decrease in ,SLC1A5," cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s2,T4,T17,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in ",SLC1A5, cleavage prior but not following ,paclitaxel," treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s3,T5,T6,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that ",SLC1A5," undergoes misfolding following ERS, consistent with ",RNF5," recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s4,T18,T19,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated ",paclitaxel,-induced SLC1A5/,38A2," degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s4,T7,T18,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. ",RNF5, KD attenuated ,paclitaxel,"-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s4,T7,T19,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. ",RNF5, KD attenuated paclitaxel-induced SLC1A5/,38A2," degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s4,T7,T8,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. ",RNF5, KD attenuated paclitaxel-induced ,SLC1A5,"/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s4,T18,T8,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated ",paclitaxel,-induced ,SLC1A5,"/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s4,T8,T19,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced ",SLC1A5,/,38A2," degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s5,T20,T10,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/",38A2, increased after ,RNF5," KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s5,T10,T21,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/38A2 increased after ",RNF5, KD in ,paclitaxel,"-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s5,T20,T21,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both SLC1A5/",38A2, increased after RNF5 KD in ,paclitaxel,"-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s5,T9,T10,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both ",SLC1A5,/38A2 increased after ,RNF5," KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s5,T9,T20,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both ",SLC1A5,/,38A2," increased after RNF5 KD in paclitaxel-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
25759021_16,s5,T9,T21,"Since RNF5 is implicated in the clearance of misfolded proteins as part of the ERAD response, we asked whether RNF5 interaction with Gln-carrier proteins required changes in protein folding following ERS. To do so, we subjected BCa cells to 35S-methionine-cysteine-based labeling followed by immunopurification of 35S-labeled SLC1A5 and limited proteolytic cleavage using BNPS-Skatole. SDS-PAGE analysis followed by autoradiography revealed a marked decrease in SLC1A5 cleavage prior but not following paclitaxel treatment (Figure 4G, S4B). These findings suggest that SLC1A5 undergoes misfolding following ERS, consistent with RNF5 recognition of misfolded proteins at the ER membrane. RNF5 KD attenuated paclitaxel-induced SLC1A5/38A2 degradation (Figure 4H). Likewise, the half-lives of both ",SLC1A5,/38A2 increased after RNF5 KD in ,paclitaxel,"-treated MDA-MB-231 cells (Figure 4I).
",Not_a_complex
